What is the overview of laryngeal carcinoma, including introduction, TNM staging, diagnostic work‑up, management options, and radiotherapy considerations for each stage?

Laryngeal Carcinoma: Comprehensive Overview

Introduction

Laryngeal carcinoma is the second most common head and neck malignancy, with over 95% being squamous cell carcinoma, affecting predominantly men with an overall 5-year survival of approximately 60.7% 1. The disease presents with distinct anatomic subsites—glottic (true vocal cords), supraglottic (above vocal cords), and subglottic (below vocal cords)—each with different metastatic patterns and prognoses 2. Primary risk factors include tobacco and alcohol use, HPV infection, and occupational exposures 2. The larynx serves critical functions in phonation, respiration, and deglutition, making treatment selection crucial for both survival and quality of life 3.

Early-stage disease (T1-T2) achieves 80-90% cure rates, while locally advanced tumors (T3-T4) have approximately 60% survival 4. Despite advances in treatment, mortality has remained relatively unchanged since the 1970s, with most patients still presenting with locally advanced disease 1.

---

TNM Staging

The AJCC 7th edition staging system classifies laryngeal cancer based on subsite-specific criteria 5:

T Stage (Primary Tumor)

• Tis: Carcinoma in situ
• T1: Tumor limited to one subsite with normal vocal cord mobility
• T2: Tumor extends to adjacent subsites or impairs vocal cord mobility
• T3: Tumor confined to larynx with vocal cord fixation and/or invades paraglottic space, inner cortex of thyroid cartilage
• T4a (moderately advanced): Invades through thyroid cartilage, extends to tissues beyond larynx
• T4b (very advanced): Invades prevertebral space, encases carotid artery, or invades mediastinal structures

N Stage (Regional Nodes)

Standard head and neck nodal staging applies, with N0 indicating no nodal involvement and N1-N3 reflecting increasing nodal burden.

Stage Grouping

• Stage I-II: Small primary tumors (T1-T2) without nodal involvement
• Stage III: Larger tumors or any T with N1 disease
• Stage IVA: Moderately advanced local/regional disease (T4a or N2)
• Stage IVB: Very advanced local/regional disease (T4b or N3)
• Stage IVC: Distant metastatic disease

The terminology shift from "resectable/unresectable" to "moderately/very advanced" reflects that many anatomically resectable tumors are now treated nonsurgically 5.

---

Diagnostic Work-Up

Clinical Evaluation

Perform flexible laryngoscopy to assess:

• Tumor location, size, and subsite involvement
• Vocal cord mobility (critical for T staging)
• Extent of mucosal involvement
• Airway patency

Imaging

• Contrast-enhanced CT of neck and chest: Primary modality for assessing cartilage invasion, extralaryngeal extension, nodal metastases, and distant disease 6
• MRI: Superior for soft tissue detail, particularly paraglottic space invasion
• PET/CT: For advanced disease, detecting occult metastases and treatment response assessment 6

Key imaging findings that alter management:

• Inner cortex cartilage invasion (ICCI)
• Extralaryngeal extension
• Tumor volume >5 mL (associated with 3-fold increased local failure risk in T3 disease) 7
• Regional nodal metastases

Pathologic Confirmation

Direct laryngoscopy with biopsy under anesthesia provides:

• Histologic confirmation
• Accurate assessment of tumor extent
• Evaluation of bilateral vocal cord mobility
• Assessment for synchronous primaries

Functional Assessment

Mandatory pretreatment evaluation includes:

• Voice quality assessment by speech pathologist
• Swallowing function evaluation
• Nutritional status
• Smoking cessation counseling 1

---

Management by Stage

Stage I-II (T1-T2, N0)

All patients with T1-T2 laryngeal cancer should be treated with intent to preserve the larynx using single-modality therapy 1.

Treatment Options (Equal Survival)

1. Endoscopic resection (preferred in experienced hands) 1

   • Transoral laser microsurgery (TLM)
   • Achieves tumor-free margins without need for postoperative RT
   • Superior functional outcomes when complete resection possible
   • Reserves RT for potential second primary tumors

2. Radiation therapy

   • 60-70 Gy over 6-7 weeks
   • Excellent voice preservation for T1 glottic lesions
   • Longer treatment duration and cost

3. Open partial laryngectomy (when endoscopic approach not feasible)

Critical principle: Surgery must achieve tumor-free margins. Surgery that anticipates need for postoperative RT due to close/involved margins is NOT acceptable 1.

Special Considerations

• Unfavorable T2 disease (deeply invasive, N+ disease, or when total laryngectomy would be only surgical option): Consider concurrent chemoradiotherapy 1
• Glottic T1-T2: Regional nodal involvement unusual; single-modality treatment to primary site sufficient 1
• Supraglottic T1-T2: Higher risk of occult nodal metastases; address regional nodes

Avoid combining surgery with RT—functional outcomes are compromised by combined-modality therapy 1.

Salvage

Local recurrence after RT may be salvaged with organ-preservation surgery, though total laryngectomy necessary for substantial proportion, especially T2 tumors 1.

---

Stage III-IV (T3-T4)

For selected patients with extensive T3 or large T4a lesions and/or poor pretreatment laryngeal function, total laryngectomy provides better survival and quality of life than organ-preservation approaches and is the preferred treatment 1.

Patient Selection Algorithm

Candidates for Organ Preservation:

• Low-volume T3 disease
• Selected T4a without extensive cartilage destruction
• Good pretreatment laryngeal function
• No deep tongue base invasion (supraglottic)
• Tumor volume ≤5 mL 7
• Patient able to comply with intensive follow-up

Candidates for Primary Total Laryngectomy:

• Extensive T3 or large T4a lesions
• Poor pretreatment laryngeal function
• Extensive cartilage invasion through outer cortex
• T4b disease (very advanced)
• Extensive supraglottic tumors with deep tongue invasion
• Medical contraindications to chemoradiotherapy

Organ-Preservation Options

1. Concurrent Chemoradiotherapy (Preferred for Organ Preservation)

Concurrent CRT offers significantly higher larynx preservation than RT alone or induction chemotherapy followed by RT, with cisplatin as the drug of choice 1.

• Regimen: Cisplatin 100 mg/m² on days 1,22,43 + RT 70 Gy
• Outcomes:
  • Higher larynx preservation rates
  • No improvement in overall survival vs. RT alone
  • Higher acute in-field toxicities
• Larynx preservation rate: Approximately 70-80% at 5 years

2. Induction Chemotherapy Followed by RT

• Cisplatin/5-FU for 2-3 cycles
• RT (70 Gy) for responders
• Complete response correlates with T stage: 82% for T2, 48% for T3, 0% for T4 1
• Lower larynx preservation than concurrent CRT
• Fewer distant metastases

3. Organ-Preserving Surgery

• Transoral laser microsurgery: Select T3 lesions with adequate exposure
• Supracricoid partial laryngectomy: T2 and selected T3 supraglottic cancers
  • 5-year local control: 100% for T2, 96% for T3 1
  • 94% adequate swallowing without gastrostomy
  • Functional outcomes optimal when complete resection without RT needed

Critical caveat: 56% of T4 cancers ultimately require salvage laryngectomy, particularly with glottic subsite and gross cartilage invasion 1.

Primary Total Laryngectomy

• Indications: Extensive T3/T4a, T4b, poor baseline function
• Adjuvant RT indicated for:
  • Positive margins (R1)
  • Cartilage infiltration
  • Pre-epiglottic space invasion
  • Paratracheal/subglottic extension >1 cm
  • Perineural invasion
  • Grade III-IV histology
  • Emergency tracheostomy
  • Any positive neck dissection 8

---

Radiotherapy Considerations by Stage

Stage I-II (T1-T2, N0)

Definitive RT Alone:

• Dose: 60-66 Gy for T1, 66-70 Gy for T2
• Fractionation: Conventional (2 Gy/fraction, 5 days/week)
• Target volume: Primary site only for glottic lesions
• Nodal coverage: Include bilateral neck levels II-IV for supraglottic primaries

Outcomes:

• T1 glottic: 90-95% local control
• T2 glottic: 70-80% local control
• Voice preservation excellent for T1, acceptable for T2

Postoperative RT (if margins positive despite re-excision):

• 60-66 Gy to tumor bed
• Compromises functional outcomes—avoid this scenario through proper surgical planning 1

---

Stage III (T3 or N1)

Concurrent Chemoradiotherapy (Organ Preservation):

• RT dose: 70 Gy in 35 fractions over 7 weeks
• Chemotherapy: Cisplatin 100 mg/m² days 1,22,43
• Target volumes:
  • High-dose CTV: Primary tumor + involved nodes (70 Gy)
  • Intermediate-dose CTV: High-risk subclinical disease (63 Gy)
  • Low-dose CTV: Elective nodal regions (56 Gy)
• Technique: IMRT preferred to spare salivary glands and reduce dysphagia

Alternative: Hyperfractionation RT

• 1.2 Gy twice daily to 76.8-81.6 Gy
• May improve local control in selected cases 8

Postoperative RT (After Partial Laryngectomy):

• Indications: Close margins, cartilage invasion, N+ disease
• Dose: 60-66 Gy (negative margins), 66-70 Gy (positive margins)
• Start: Within 6 weeks of surgery

---

Stage IVA (T4a or N2-N3)

Concurrent Chemoradiotherapy (Selected Low-Volume T4a):

• Same regimen as Stage III
• Exclude: Extensive cartilage destruction, deep tongue invasion
• Requires: Intensive surveillance for early salvage

Postoperative Chemoradiotherapy (After Total Laryngectomy):

• Indications:
  • Positive margins
  • ≥2 positive nodes
  • Extranodal extension
  • pT4 disease
  • Perineural/lymphovascular invasion
• Regimen: RT 60-66 Gy + concurrent cisplatin 100 mg/m² weekly or 3-weekly
• Start: Within 6 weeks of surgery

---

Stage IVB (T4b or Unresectable N3)

Definitive Chemoradiotherapy:

• RT: 70 Gy with concurrent cisplatin
• Prognosis: Poor, with high rates of local failure and distant metastases
• Consider: Clinical trial enrollment
• Palliative intent: If performance status poor or extensive comorbidities

Salvage laryngectomy rates approach 70-80% for T4b disease—primary surgery often more appropriate 1.

---

Regional Nodal Management

Glottic Carcinoma

• T1-T2a: No elective nodal treatment (nodal involvement <5%)
• T2b-T4: Bilateral neck RT (levels II-IV) or selective neck dissection

Supraglottic Carcinoma

• All stages: Bilateral neck treatment required (nodal involvement 30-50%)
• RT: Include levels II-IV bilaterally
• Surgery: Bilateral selective neck dissection (levels II-IV)

Subglottic Carcinoma

• All stages: Include paratracheal and level VI nodes
• Highest risk of tracheoesophageal groove involvement

---

Critical Pitfalls and Caveats

1. Avoid combined surgery + RT for early-stage disease—functional outcomes significantly worse 1

2. Do not plan surgery with anticipated positive margins requiring adjuvant RT—this is unacceptable practice 1

3. Patient selection for organ preservation is critical—extensive T3/T4a with poor baseline function should undergo primary laryngectomy 1

4. Tumor volume >5 mL in T3 disease predicts 3-fold higher local failure—consider this in treatment selection 7

5. Active surveillance mandatory after organ preservation—early salvage laryngectomy essential for treatment failures

6. Pretreatment functional assessment non-negotiable—voice and swallowing evaluation guides treatment selection 1

7. Reserve RT for second primaries when possible—endoscopic surgery preferred for T1-T2 when feasible 1

8. Cisplatin is the only chemotherapy agent with strong evidence for concurrent use with RT 1